Prof. Marx (Aachen, Germany)

Let’s look at glycaemic control: glycaemic control was similar and here we look at hypoglycaemia risk,these drugs do not lead to hypoglycaemia and, despite an improvement in glucose control, we did not see an increase in hypoglycaemic events in linagliptin-treated compared to placebo groups. That included any hypos as well as severe and moderate hypoglycaemic events.

With respect to additional side effects, there was [a] small numerical increase here in acute pancreatitis, a side effect that is known with DPP4 inhibitors, but as you can see here, very small number of patients.